secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001654954-24-001923
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics expands levosimendan license to worldwide rights from Orion
------------------------------------------------------------------------------

- Amendment expands Tenax's exclusive global rights to levosimendan for PH-HFpEF from North America to worldwide.
- Royalty rates improved to high single-digit to low-teen percentages; maximum cost of goods reduced.
- Milestone payments: $10M on US FDA approval (increased), $5M on Japan approval; up to $45M for commercial milestones.
- Tenax retains right of first negotiation for all indications except neurological, which are excluded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001923/0001654954-24-001923-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495424001923/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-001923

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer